bTranscutaneous immunization (TCI) is a noninvasive strategy to induce protective immune responses. We describe TCI with a band-aid vaccine placed on the postauricular skin to exploit the unique organization of the stratum corneum and to promote the development of immune responses to resolve active experimental otitis media due to nontypeable Haemophilus influenzae (NTHI). This therapeutic immunization strategy induced significantly earlier resolution of middle ear fluid and rapid eradication of both planktonic and mucosal biofilm-resident NTHI within 7 days after receipt of the first immunizing band-aid vaccine. Efficacy was ascribed to the homing of immunogen-bearing cutaneous dendritic cells to the nasal-associated lymphoid tissue, induction of polyfunctional CD4 ؉ T cells, and the presence of immunogen-specific IgM and IgG within the middle ear. TCI using band-aid vaccines could expand the use of traditional parenteral preventative vaccines to include treatment of active otitis media, in addition to other diseases of the respiratory tract due to NTHI.T ranscutaneous immunization (TCI) offers multiple advantages as an immunization strategy; it is noninvasive, which may aid in acceptance and compliance, and reduced costs are associated with vaccine production and administration, as delivery devices may be simplified or eliminated and trained medical personnel are not required, characteristics that could allow for vaccine distribution beyond developed countries (1, 2). TCI induces both systemic and mucosal immune responses (3-6), important features as the mucosae represent critical defensive barriers that also respond immunologically to insults (7). Thus, TCI exhibits potential as a simple efficacious method to induce protective immune responses and thereby limit disease.One of the most common diseases of childhood is otitis media (OM). It is estimated that 709 million cases of acute OM and 65 million to 330 million episodes of chronic secretory OM occur each year worldwide (8, 9). While deaths due to OM are not common in developed countries, complications of chronic suppurative OM result in the deaths of 50,000 children Ͻ5 years of age in developing countries (10, 11). Furthermore, morbidity associated with OM is significant for all children worldwide. Nontypeable Haemophilus influenzae (NTHI) is the predominant pathogen in chronic OM, recurrent OM, and OM associated with treatment failure, and NTHI biofilms within the middle ear contribute significantly to pathogenesis (12, 13). Biofilms within the middle ear facilitate the chronicity and recalcitrance of OM and often require prolonged treatment with an antimicrobial. This management strategy is of concern due to the emergence of multiple antibioticresistant bacteria (14, 15). Thus, it is desirable develop better methods to manage OM.Previous work demonstrated that TCI with chimV4, a novel chimeric antigen that targets the critical NTHI adhesins OMP P5 and the type IV pilus (Tfp) (16), admixed with the adjuvant LT(R192G/L211A), a double mutant of Escherichia ...